|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500110034 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-29 09:47:52 |
|
注册时间: Date of Registration: |
2025-09-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于认知行为疗法的线上自助式抑郁防复发干预研究 |
|
Public title: |
The effectiveness of online guided self-help intervention for depressive symptoms: Evidences from randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
hope 在线心理干预 RCT 研究 |
|
Scientific title: |
Hope Online Psychological Intervention RCT Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
付思南 |
研究负责人: |
毛宁宁 |
|
Applicant: |
Fu Sinan |
Study leader: |
Mao Ningning |
|
申请注册联系人电话: Applicant telephone: |
+86 183 1063 5143 |
研究负责人电话: Study leader's telephone: |
+86 159 1032 8718 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sinannancyfu@mail.bnu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
11132023072@bnu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市海淀区新街口外大街19号 |
研究负责人通讯地址: |
中国北京市海淀区新街口外大街19号 |
|
Applicant address: |
Xinjiekou Wai Street 19, Haidian District, Beijing, China |
Study leader's address: |
Xinjiekou Wai Street 19, Haidian District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100875 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
北京师范大学 |
||
|
Applicant's institution: |
Beijing Normal University |
||
|
研究负责人所在单位: |
北京师范大学 |
||
|
Affiliation of the Leader: |
Beijing Normal University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
BNU202401170006 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京师范大学心理学部伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of the Faculty of Psychology,BNU |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-26 00:00:00 |
||
|
伦理委员会联系人: |
熊炳森 |
||
|
Contact Name of the ethic committee: |
Xiong Bingsen |
||
|
伦理委员会联系地址: |
北京市新街口外大街19号北京师范大学后主楼 |
||
|
Contact Address of the ethic committee: |
Back main Building, Beijing Shifan University, 19 Xinjiekou Wai Street, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5880 8866 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xiongbingsen@bnu.edu.cn |
|
研究实施负责(组长)单位: |
北京师范大学心理学部 |
||||||||||||||||||||||
|
Primary sponsor: |
Faculty of Psychology, Beijing Normal University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国北京市海淀区新街口外大街19号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Xinjiekou Wai Street 19, Haidian District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
博后院; 地平线数字医疗(深圳)有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Postdoctoral Station; Horizon Digital Healthcare (Shenzhen) Co., Ltd. |
||||||||||||||||||||||
|
Target disease: |
Depressive symptoms |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在探究一项基于认知行为疗法和正念冥想技术的指导性线上自助式干预产品(LotusHope)对于缓解抑郁症状、提升用户心理健康的效果,并比较该项目在临床与亚临床群体之间的效果差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to investigate the effectiveness of a guided online self-help intervention product (LotusHope) based on cognitive behavioral therapy and mindfulness meditation techniques in alleviating depressive symptoms and improving the mental health of users. We also aim to varifying the difference of the effectiveness of this program on clinical and subclinical populations. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
临床组 1. 年龄在18岁以上 2. 能够熟练使用智能手机 3. PHQ-9评分在5分及以上 4. 经专业精神检查确诊为至少一种心境障碍 亚临床组 1. 年龄在18岁以上 2. 能够熟练使用智能手机 3. PHQ-9评分在5分及以上 4. 未被确认为任一心境障碍 |
||||||||||||||||||||||
|
Inclusion criteria |
Clinical Group 1. Age among 18 2. Proficient in using smart phones 3. PHQ-9 score of 5 or above 4. Diagnosed with at least one mood disorder Subclinical group 1. Age among 18 2. Proficient in using smart phones 3. PHQ-9 score of 5 or above 4. Had not been diagnosed with any mood disorder |
||||||||||||||||||||||
|
排除标准: |
临床组 1. 重大自杀倾向 2. 脑部器质性病变 3. 严重精神病性症状 4. 共病广泛性焦虑障碍以外其他的心理障碍 5. 干预前4周内和最后一次测量前服药方案出现变化 6. 干预开始前两周内和最后一次测量前参与过其他心理治疗 7. 拒绝参与 亚临床组 1. 重大自杀倾向 2. 脑部器质性病变 3. 严重精神病性症状 4. 干预开始前两周内和最后一次测量前参与过其他心理治疗 5. 拒绝参与 |
||||||||||||||||||||||
|
Exclusion criteria: |
Clinical Group 1. Major suicidality 2. Organic lesions of the brain 3. Severe psychotic symptoms 4. Comorbid psychological disorders other than generalized anxiety disorder 5. Changes in medication regimen occurred within 4 weeks before the intervention and before the last measurement 6. Having participated in other psychotherapies within two weeks before the start of the intervention and before the last measurement 7. Refuse to participate. Subclinical group 1. Major suicidality 2. Organic lesions of the brain 3. Severe psychotic symptoms 4. Having participated in other psychotherapies within two weeks before the start of the intervention and before the last measurement 5. Refuse to participate |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-20 00:00:00至 To 2024-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-02-20 00:00:00 至 To 2024-03-23 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机化方案采用“分层+区块”组合设计,具体流程如下: 分层阶段:使用计算机自动随机系统,以“是否有心境障碍确诊经历”作为核心分层变量,将符合纳排标准的参与者划分为“临床层”(经专业精神检查确诊至少一种心境障碍)和“亚临床层”(未确诊任一心境障碍)两个独立层级,确保两层参与者分别进行后续随机分配,避免“临床/亚临床”群体混杂对干预效果比较的干扰。 层内区块随机阶段:在“临床层”和“亚临床层”内部,分别采用区块随机法,通过计算机随机分组程序将参与者按1:1比例分配至在线指导性自助组(IGSH组)和等待控制组(WLC组)。每个区块内固定分配半数参与者至IGSH组、半数至WLC组,保证每层内两组样本量在招募全过程中始终均衡,避免分阶段招募导致的组间样本失衡。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The randomization protocol employs a stratified + blocked design, with the following specific procedures: Stratification Phase: Using a computerized randomization system, participants meeting inclusion/exclusion criteria are stratified based on the core variable "history of a diagnosed mood disorder," dividing them into two independent strata: the "Clinical Stratum" (participants with a confirmed diagnosis of at least one mood disorder via professional psychiatric evaluation) and the "Subclinical Stratum" (participants with no confirmed diagnosis of any mood disorder). This ensures that participants in each stratum are randomized separately, preventing confounding effects between clinical and subclinical groups on the comparison of intervention outcomes. Within-Stratum Blocked Randomization Phase: Within both the Clinical Stratum and the Subclinical Stratum, blocked randomization is applied using a computer-generated random assignment program to allocate participants in a 1:1 ratio to either the Internet-Based Guided Self-Help group (IGSH group) or the Waitlist Control group (WLC group). Within each block, exactly half of the participants are assigned to the IGSH group and the other half to the WLC group, ensuring balanced sample sizes between the two groups throughout the entire recruitment process and preventing imbalances due to staggered enrollment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据将在主要研究成果发表后 6 个月予以公开,通过国内临床试验公共管理平台(网址:http://www.medresman.org.cn)共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data will be made public 6 months after the publication of the main research results, and we will share the original data through the Clinical Trial Public Management Platform (website: http://www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集使用问卷星平台和 Qualtrics 平台开展。收集完成后,会立即导出数据以保障安全性。对于通过 Qualtrics 平台采集的数据,导出后会第一时间转移至国内安全服务器,之后使用 SPSS 26.0 进行数据录入、清洗、存储和管理。数据采集过程中,严格遵循隐私保护原则:对涉及研究对象个人身份等敏感信息进行去标识化处理,仅保留研究所需的非标识化数据字段。所有数据由经过培训的研究人员依据研究方案进行采集,并通过双人独立录入及逻辑核查等方式确保数据的准确性、完整性和可靠性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is carried out using the Wenjuanxing platform and the Qualtrics platform. After collection, the data will be exported immediately to ensure security. For the data collected via the Qualtrics platform, it will be transferred to domestic secure servers as soon as possible after export, and then SPSS 26.0 will be used for data entry, cleaning, storage, and management. During the data collection process, the principle of privacy protection is strictly followed: sensitive information related to the personal identities of research subjects is de-identified, and only non-identifiable data fields required for the study are retained. All data is collected by trained researchers in accordance with the research protocol, and the accuracy, completeness, and reliability of the data are ensured through methods such as double independent data entry and logical verification. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |